A single-center, open-label, phase II, safety, pharmacokinetic and efficacy [study] of Panzem Nanocrystal Colloidal Dispersion [2-methoxyestradiol] administered orally to patients with recurrent glioblastoma multiforme
Phase of Trial: Phase II
Latest Information Update: 02 Oct 2014
At a glance
- Drugs 2-methoxyestradiol (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors EntreMed
- 09 Dec 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 26 Apr 2008 The expected completion date for this trial is 1 Jul 2008.
- 29 Mar 2006 New trial record.